Influence of single-nucleotide polymorphisms on deferasirox Ctrough levels and effectiveness

Deferasirox (DFX) is the only once-daily oral chelator for iron overload and its pharmacokinetic has been related with response to therapy. Our aim was to evaluate DFX plasma concentrations according to single-nucleotide polymorphisms in genes involved in its metabolism ( UGT1A1, UGT1A3 , CYP1A1 , C...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The pharmacogenomics journal 2015-06, Vol.15 (3), p.263-271
Hauptverfasser:	Cusato, J, Allegra, S, Massano, D, De Francia, S, Piga, A, D'Avolio, A
Format:	Artikel
Sprache:	eng
Schlagworte:	45 45/22 45/77 631/154/436/1729 631/154/436/434 631/208/721 631/208/726/649 692/699/1541 Biomedical and Life Sciences Biomedicine CYP1A2 protein CYP2D6 protein Cytochrome P450 Dosage Gene Expression Genotypes High performance liquid chromatography Human Genetics Iron Liquid chromatography Metabolism Oncology original-article Pharmacokinetics Pharmacotherapy Plasma Psychopharmacology Single-nucleotide polymorphism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!